Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease

Antiviral Research

Volumn 34, Issue 1, 1997, Pages 1-15

  Pretzer, Elizabeth ^a   Flasher, Diana ^a   Düzgüneş, Nejat ^a,b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MACROPHAGE; PRIORITY JOURNAL; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030950470     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(96)01017-0     Document Type: Article

References (69)

1. Allen, T.M., Hansen, C., Martin, F., Redemann, C. and Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066, 29-36.
2. Allen, T.M., Mehra, T., Hansen, C. and Chin, Y.C. (1992) Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res. 52, 2431-2439.
3. Allen, T.M., Hansen, C.B. and Guo, L.S.S. (1993) Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150, 9-16.
4. Allen, T.M. (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15, 215-220.
5. Alving, C.R. (1983) Delivery of liposome-encapsulated drugs to macrophages. Pharmacol. Ther. 22, 407-422.
6. Ashorn, P., McQuade, T.J., Thaisrivongs, S., Tomasselli, A.G., Tarpley, W.G. and Moss, B. (1990) An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. USA 87, 7472-7476.
7. Baboonian, C., Dalgleish, A., Bountiff, L., Gross, J., Oroszlan, S., Rickett, G., Smith-Burchnell, C., Troke, P. and Merson, J. (1991) HIV-1 proteinase is required for synthesis of pro-viral DNA. Biochem. Biophys. Res. Commun. 179, 17-24.
8. Bakker-Woudenberg, I.A.J.M., Lokerse, A.F., Ten Kate, M.T., Melissen, P.M.B., Van Vianen, W. and Van Etten, E.W.M. (1993) Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections. Eur. J. Clin. Microbiol. Infect. Dis. 12, Suppl. 1, 61-67.
9. Bartlett, G.R. (1959) Phosphorus assay in column chromatography. J. Biol. Chem. 234, 466-468.
10. Bender, A.R., Von Briesen, H., Kreuter, J., Duncan, I.B. and Rübsamen-Waigmann, H. (1996) Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/ macrophages in vitro. Antimicrob. Agents Chemother. 40, 1467-1471.
11. Daleke, D.L., Hong, K. and Papahadjopoulos, D. (1990) Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024, 352-366.
12. Désormeaux, A., Harvie, P., Perron, S., Makabi-Panzu, B., Beauchamp, D., Tremblay, M., Poulin, L. and Bergeron, M.G. (1994) Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 8, 1545-1553.
13. Dusserre, N., Lessard, C., Paquette, N., Perron, S., Poulin, L., Tremblay, M., Beauchamp, D., Désormeaux, A. and Bergeron, M.G. (1995) Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 9, 833-841.
14. Düzgüneş, N., Perumal, V.K., Kesavalu, L., Goldstein, J.A., Debs, R.J. and Gangadharam, P.R.J. (1988) Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex in beige mice. Antimicrob. Agents Chemother. 32, 1404-1411.
15. Düzgüneş, N., Ashtekar, D.R., Flasher, D.L., Ghori, N., Debs, R.J., Friend, D.S. and Gangadharam, P.R.J. (1991) Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J. Infect. Dis. 164, 143-151.
16. Embretson, J., Zupancic, M., Ribas, J.L., Burke, A., Racz, P., Tenner-Racz, K. and Haase, A.T. (1993) Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-362.
17. 2 symmetric inhibitor complexed to HIV-1 protease. Science 249, 527-533.
18. Ezzell, C. (1996) Emergence of the protease inhibitors: a better class of AIDS drugs? J. NIH Res. 8(1), 41-45.
19. Gabizon, A.A. (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52, 891-896.
20. Gartner, S., Markovits, P., Markovitz, D.M., Kaplan, M.H., Gallo, R.C. and Popovic, M. (1986) The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219.
21. Gonzalez-Rothi, R.J., Straub, L., Cacace, J.L. and Schreier, H. (1991) Liposomes and pulmonary alveolar macrophages: functional and morphologic interactions. Exp. Lung Res. 17, 687-705.
22. Harvie, P., Désormeaux, A., Gagné, N., Tremblay, M., Poulin, L., Beauchamp, D. and Bergeron, M.G. (1995) Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 9, 701-707.
23. Harvie, P., Désormeaux, A., Bergeron, M.-C., Tremblay, M., Beauchamp, D., Poulin, L. and Bergeron, M.G. (1996) Comparative pharmacokinetics, distribution in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′,3′-dideoxyinosine. Antimicrob. Agents Chemother. 40, 225-229.
24. Ho, D.D., Rota, T.R. and Hirsch, M.S. (1986) Infection of monocyte/macrophages by human T lymphotropic virus type III. J. Clin. Invest. 77, 1712-1715.
25. Huang, S.K., Lee, K.-D., Hong, K., Friend, D.S. and Papahadjopoulos, D. (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135-5143.
26. Huff, J.R. (1991) HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34, 2305-2314.
27. Kageyama, S., Anderson, B.D., Hoesterey, B.L., Hayashi, H., Kiso, Y., Flora, K.P. and Mitsuya, H. (1994a) Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38, 1107-1111.
28. 2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res. Hum. Retroviruses 10, 735-743.
29. Kaledin, V.I., Matienko, N.A., Nikolin, V.P., Gruntenko, Y.V., Budker, V.G. and Vakhrusheva, T.E. (1982) Subcutaneously injected radiolabeled liposomes: transport to the lymph nodes in mice. JNCI 69, 67-71.
30. Kaplan, A.H., Manchester, M. and Swanstrom, R. (1994) The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68, 6782-6786.
31. Kay, J. and Dunn, B.M. (1990) Viral proteinases: weakness in strength. Biochim. Biophys. Acta 1048, 1-18.
32. Kedar, E., Braun, E., Rutkowski, Y., Emanuel, N. and Barenholz, Y. (1994) Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J. Immunother. 16, 115-124.
33. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35, 2209-2214.
34. Kempf, D.J., Marsh, K.C., Denissen, J.F., McDonald, E., Vasavanonda, S., Flentge, C.A., Green, B.E., Fino, L., Park, C.H., Kong, X.-P., Wideburg, N.E., Saldivar, A., Ruiz, L., Kati, W.M., Sham, H.L., Robins, T., Stewart, K.D., Hsu, A., Plattner, J.J., Leonard, J.M. and Norbeck, D.W. (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92, 2484-2488.
35. Kesavalu, L., Goldstein, J.A., Debs, R.J., Düzgüneş, N. and Gangadharam, P.R.J. (1990) Differential effects of free and liposome encapsulated amikacin on the growth of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle 71, 215-218.
36. Kim, S., Scheerer, S., Geyer, M.A. and Howell, S.B. (1990) Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J. Infect. Dis. 162, 750-752.
37. Konopka, K., Davis, B.R., Larsen, C.E., Alford, D.R., Debs, R.J. and Düzgüneş, N. (1990) Liposomes modulate human immunodeficiency virus infectivity. J. Gen. Virol. 71, 2899-2907.
38. Lee, K.-D., Nir, S. and Papahadjopoulos, D. (1993) Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32, 889-899.
39. Lin, J.H., Chen, I.-W. and King, J. (1992) Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. J. Pharmacol. Exp. Ther. 263, 105-111.
40. Majumdar, S., Flasher, D., Friend, D.S., Nassos, P., Yajko, D., Hadley, W.K. and Düzgüneş, N. (1992) Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/ macrophages. Antimicrob. Agents Chemother. 36, 2808-2815.
41. Makabi-Panzu, B., Lessard, C., Perron, S., Désormeaux, A., Tremblay, M., Poulin, L., Beauchamp, D. and Bergeron, M.G. (1994) Comparison of cellular accumulation, tissue distribution, and anti-HIV activity of free and liposomal 2′,3′-dideoxycytidine. AIDS Res. Hum. Retroviruses 10, 1463-1470.
42. + cell line H9. AIDS Res. Hum. Retroviruses 5, 253-255.
43. Meek, T.D., Lambert, D.M., Dreyer, G.B., Carr, T.J., Tomaszek, T.A., Jr., Moore, M.L., Strickler, J.E., Debouck, C., Hyland, L.J., Matthews, T.J., Metcalf, B.W. and Petteway, S.R. (1990) Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343, 90-92.
44. Meltzer, M.S., Skillman, D.R., Gomatos, P.J., Kalter, D.C. and Gendelman, H.E. (1990) Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. Rev. Immunol. 8, 169-194.
45. Pantaleo, G., Graziosi, C., Butini, L., Pizzo, P.A., Schnittman, S.M., Kotler, D.P. and Fauci, A.S. (1991) Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 9838-9842.
46. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, J.M., Kotler, D.P. and Fauci, A.S. (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
47. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.-D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88, 11460-11464.
48. Perno, C.-F., Bergamini, A., Pesce, C.D., Milanese, G., Capozzi, M., Aquaro, S., Thaisrivongs, S., Tarpley, W.G., Zon, G., D'Agostini, C., Rocchi, G., Garaci, E. and Calió, R. (1993) Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis. 168, 1148-1156.
49. Popescu, M.C., Swensen, C.E. and Ginsberg, R.S. (1987) Liposome-mediated treatment of viral, bacterial and protozoal infections. In: M.J. Ostro, (Ed), Liposomes: From Biophysics to Therapeutics, pp. 219-251, Marcel Dekker, New York.
50. Popovic, M., Read-Connole, E. and Gallo, R.C. (1984a) T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet (ii), 1472-1473.
51. Popovic, M., Sarngadharan, M.G., Read, E. and Gallo, R.C. (1984b) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500.
52. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. (1982) Analysis of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42, 1412-1422.
53. Pretzer, E., Flasher, D. and Düzgüneş, N. (1995) Inhibition of HIV-1 infection of macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease. Antiviral Res. 26, A358 (Abstr.).
54. Raz, A., Bucana, C., Fogler, W.E., Poste, G. and Fidler, I.J. (1981) Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41, 487-494.
55. Roberts, N.A., Martin, J.A., Kinchington, D., Broadhurst, A.V., Craig, J.C., Duncan, I.B., Galpin, S.A., Handa, B.K., Kay, J., Kröhn, A., Lambert, R.W., Merrett, J.H., Mills, J.S., Parkes, K.E.B., Redshaw, S., Ritchie, A.J., Taylor, D.L., Thomas, G.J. and Machin, P.J. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361.
56. Robins, T. and Plattner, J. (1993) HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquired Immune Defic. Syndr. 6, 162-170.
57. Roerdink, F., Regts, J., Daemen, T., Bakker-Woudenberg, I. and Scherphof, G. (1986) Liposomes as drug carriers to liver macrophages: fundamental and therapeutic aspects. In: G. Gregoriadis, J. Senior and G. Poste (Eds), Targeting of Drugs with Synthetic Systems, pp. 193-206, Plenum, New York.
58. Rosé, J.R., Babé, L.M. and Craik, C.R. (1995) Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69, 2751-2758.
59. Schuitemaker, H. (1994) Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis? J. Leukocyte Biol. 56, 218-224.
60. Senior, J.H. (1987) Fate and behavior of liposomes in vivo. Crit. Rev. Ther. Drug Carrier Syst. 3, 123-193.
61. Szebeni, J., Wahl, S.M., Betageri, G.V., Wahl, L.M., Gartner, S., Popovic, M., Parker, R.J., Black, C.D.V. and Weinstein, J.N. (1990) Inhibition of HIV-1 in monocyte/ macrophage cultures by 2′,3′-dideoxycytidine-5′-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 6, 691-702.
62. Szoka, F.C. and Chu, C.-J. (1988) Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob. Agents Chemother. 32, 858-864.
63. Szoka, F.C. Jr. (1991) Liposomal drug delivery. Current status and future prospects. In: J. Wilschut and D. Hoekstra (Eds), Membrane Fusion, pp. 845-890. Marcel Dekker, New York.
64. 1 phenyl substituents: X-ray crystal structure assisted design. J. Med. Chem. 35, 1685-1701.
65. Tomioka, H., Saito, H., Sato, K. and Yoneyama, T. (1991) Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am. Rev. Respir. Dis. 144, 575-579.
66. Torre-Cisneros, J., Villanueva, J.L., Kindelan, J.M., Jurado, R. and Sanchez-Guijo, P. (1993) Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 17, 625-627.
67. Van Etten, E.W.M., Ten Kate, M.T., Stearne, L.E.T. and Bakker-Woudenberg, I.A.J.M. (1995) Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity and efficacy in systemic candidiasis in leukopenic mice. Antimicrob. Agents Chemother. 39, 1954-1958.
68. Venaud, S., Yahi, N., Fehrentz, J.L., Guettari, N., Nisato, D., Hirsch, I. and Chermann, J.C. (1992) Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication. Res. Virol. 143, 311-319.
69. Woodle, M.C. and Lasic, D.D. (1992) Sterically stabilized liposomes. Biochim. Biophys. Acta 1113, 171-199.